查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571766

人類胚胎幹細胞市場規模、佔有率、趨勢分析報告：按應用、地區、細分市場預測，2024-2030

Human Embryonic Stem Cells Market Size, Share & Trends Analysis Report By Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

人類胚胎幹細胞市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球人類胚胎幹細胞市場規模預計將達到40.8億美元，2024年至2030年複合年成長率為10.5%。

hESCs 技術由於其宿主-移植物組織相容性高，往往可用於人體組織工程。

發育潛力的維持，即所有三個生殖細胞層對衍生物的貢獻，是這些細胞的重要特徵。即使克隆誘導和長期未分化擴增後，這種能力仍能持續維持，從而促進攝取。

此外，這些細胞能夠表現高水平的鹼性磷酸酶（一種主要轉錄因子）和端粒酶。已發現這些因素對於維持細胞內的多功能至關重要。

此外，hESC 可以輕易分化為神經元、神經細胞、少突膠質細胞和星狀細胞。上述特徵對於研究神經發生早期發生的事件序列很有用。

然而，使用來自可行胚胎的幹細胞充滿了倫理問題，因此科學家正在探索其他方法來創建ESC。其他方法包括誘導胚胎生殖細胞、來自死亡胚胎的幹細胞以及其他技術。

人類胚胎幹細胞市場報告亮點

  • 到2023年，再生醫學將以61.1%的佔有率主導市場。再生醫學在治療多種疾病方面取得了重大進展。此外，源自人類胚胎的多功能細胞已成為生物醫學研究的焦點。
  • 幹細胞生物學研究領域預計在預測期內複合年成長率最快，達到 11.4%。一些生物製藥公司過去已經探索了幹細胞生物學的潛力。
  • 在強大的研究基礎設施機構和設施的支持下，北美的人類胚胎幹細胞將在 2023 年佔據市場主導地位。慢性病和遺傳疾病的增加對基因治療產生了巨大的需求。
  • 亞太地區人類胚胎幹細胞市場預計在預測期內將顯著成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章人類胚胎幹細胞市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 人類胚胎幹細胞市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 人類胚胎幹細胞市場：應用估算與趨勢分析

  • 細分儀表板
  • 人類胚胎幹細胞市場：2023 年和 2030 年應用變化分析
  • 再生醫學
  • 幹細胞生物學研究
  • 組織工程
  • 毒性試驗

第5章 人類胚胎幹細胞市場：區域估計與趨勢分析

  • 2023 年及 2030 年人類胚胎幹細胞市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第6章 競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Thermo Fisher Scientific, Inc.
    • STEMCELL Technologies
    • Merck KGaA
    • CellGenix GmbH
    • PromoCell GmbH
    • Takara Bio
    • Lonza
    • Cellartis AB
    • ATCC
    • AcceGen
    • Cell Applications, Inc.
    • Bio-Techne
簡介目錄
Product Code: GVR-1-68038-394-2

Human Embryonic Stem Cells Market Growth & Trends:

The global human embryonic stem cells market size is expected to reach USD 4.08 billion by 2030, registering to grow at a CAGR of 10.5% from 2024 to 2030 according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.

Human Embryonic Stem Cells Market Report Highlights:

  • Regenerative medicines dominated the market with a share of 61.1% in 2023. Regenerative medicines offer significant advancements in treating several diseases. Moreover, pluripotent cells originating from human embryos have been central to biomedical research.
  • The stem cell biology research segment is expected to witness the fastest CAGR of 11.4% over the forecast period. Several biopharmaceutical companies have explored the potency of stem cell biology in the past.
  • North America human embryonic stem cells dominated the market in 2023 owing to robust research infrastructure institutions and facilities. The rise in chronic diseases and genetic disorders has created a huge demand for gene therapies.
  • Asia Pacific human embryonic stem cell market is anticipated to witness significant growth in the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Human Embryonic Stem Cells Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Human Embryonic Stem Cells Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Human Embryonic Stem Cells Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Regenerative Medicine
    • 4.3.1. Regenerative Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Stem Cell Biology Research
    • 4.4.1. Stem Cell Biology Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tissue Engineering
    • 4.5.1. Tissue Engineering Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Toxicology Testing
    • 4.6.1. Toxicology Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis

  • 5.1. Human Embryonic Stem Cells Market Share, By Region, 2023 & 2030 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Canada Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.4. Mexico
      • 5.2.4.1. Mexico Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. UK Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Germany Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. France Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Italy Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Spain Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Denmark
      • 5.3.7.1. Denmark Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Sweden Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Norway Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. China
      • 5.4.2.1. China Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Japan Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. India Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Australia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Saudi Arabia
      • 5.6.2.1. Saudi Arabia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. UAE
      • 5.6.3.1. UAE Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. South Africa
      • 5.6.4.1. South Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis by Key Market Participants
  • 6.2. Company Categorization
  • 6.3. Company Heat Map Analysis
  • 6.4. Company Profiles
    • 6.4.1. Thermo Fisher Scientific, Inc.
      • 6.4.1.1. Participant's Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Recent Developments/ Strategic Initiatives
    • 6.4.2. STEMCELL Technologies
      • 6.4.2.1. Participant's Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Recent Developments/ Strategic Initiatives
    • 6.4.3. Merck KGaA
      • 6.4.3.1. Participant's Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Recent Developments/ Strategic Initiatives
    • 6.4.4. CellGenix GmbH
      • 6.4.4.1. Participant's Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Recent Developments/ Strategic Initiatives
    • 6.4.5. PromoCell GmbH
      • 6.4.5.1. Participant's Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Recent Developments/ Strategic Initiatives
    • 6.4.6. Takara Bio
      • 6.4.6.1. Participant's Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Recent Developments/ Strategic Initiatives
    • 6.4.7. Lonza
      • 6.4.7.1. Participant's Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Recent Developments/ Strategic Initiatives
    • 6.4.8. Cellartis AB
      • 6.4.8.1. Participant's Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Recent Developments/ Strategic Initiatives
    • 6.4.9. ATCC
      • 6.4.9.1. Participant's Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Recent Developments/ Strategic Initiatives
    • 6.4.10. AcceGen
      • 6.4.10.1. Participant's Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Recent Developments/ Strategic Initiatives
    • 6.4.11. Cell Applications, Inc.
      • 6.4.11.1. Participant's Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Recent Developments/ Strategic Initiatives
    • 6.4.12. Bio-Techne
      • 6.4.12.1. Participant's Overview
      • 6.4.12.2. Financial Performance
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Recent Developments/ Strategic Initiatives